Elevated plasma complement factor H related 5 protein is associated with venous thromboembolism

Venous thromboembolism (VTE) is a common, multi-causal disease with potentially serious short- and long-term complications. In clinical practice, there is a need for improved plasma biomarker-based tools for VTE diagnosis and risk prediction. Here we show, using proteomics profiling to screen plasma...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 14; no. 1; pp. 3280 - 23
Main Authors Iglesias, Maria Jesus, Sanchez-Rivera, Laura, Ibrahim-Kosta, Manal, Naudin, Clément, Munsch, Gaëlle, Goumidi, Louisa, Farm, Maria, Smith, Philip M., Thibord, Florian, Kral-Pointner, Julia Barbara, Hong, Mun-Gwan, Suchon, Pierre, Germain, Marine, Schrottmaier, Waltraud, Dusart, Philip, Boland, Anne, Kotol, David, Edfors, Fredrik, Koprulu, Mine, Pietzner, Maik, Langenberg, Claudia, Damrauer, Scott M., Johnson, Andrew D., Klarin, Derek M., Smith, Nicholas L., Smadja, David M., Holmström, Margareta, Magnusson, Maria, Silveira, Angela, Uhlén, Mathias, Renné, Thomas, Martinez-Perez, Angel, Emmerich, Joseph, Deleuze, Jean-Francois, Antovic, Jovan, Soria Fernandez, Jose Manuel, Assinger, Alice, Schwenk, Jochen M., Souto Andres, Joan Carles, Morange, Pierre-Emmanuel, Butler, Lynn Marie, Trégouët, David-Alexandre, Odeberg, Jacob
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 07.06.2023
Nature Publishing Group
Springer Nature
Nature Portfolio
Subjects
Online AccessGet full text
ISSN2041-1723
2041-1723
DOI10.1038/s41467-023-38383-y

Cover

More Information
Summary:Venous thromboembolism (VTE) is a common, multi-causal disease with potentially serious short- and long-term complications. In clinical practice, there is a need for improved plasma biomarker-based tools for VTE diagnosis and risk prediction. Here we show, using proteomics profiling to screen plasma from patients with suspected acute VTE, and several case-control studies for VTE, how Complement Factor H Related 5 protein (CFHR5), a regulator of the alternative pathway of complement activation, is a VTE-associated plasma biomarker. In plasma, higher CFHR5 levels are associated with increased thrombin generation potential and recombinant CFHR5 enhanced platelet activation in vitro. GWAS analysis of ~52,000 participants identifies six loci associated with CFHR5 plasma levels, but Mendelian randomization do not demonstrate causality between CFHR5 and VTE. Our results indicate an important role for the regulation of the alternative pathway of complement activation in VTE and that CFHR5 represents a potential diagnostic and/or risk predictive plasma biomarker. Improved biomarker-based tools for diagnosis and risk prediction of venous thromboembolism (VTE) are needed. Here, the authors show that Complement Factor H Related 5 protein, a regulator of the alternative pathway of complement activation, is a VTE-associated plasma biomarker in 5 independent cohorts.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Nature Communications
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-023-38383-y